Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCARDIOVASCULAR PHARMACOLOGY

Anti-inflammatory Mystixin Peptides Inhibit Plasma Leakage Without Blocking Endothelial Gap Formation

Peter Baluk, Natasha W. Fine, Holly A. Thomas, Edward T. Wei and Donald M. Mcdonald
Journal of Pharmacology and Experimental Therapeutics February 1998, 284 (2) 693-699;
Peter Baluk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natasha W. Fine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly A. Thomas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward T. Wei
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald M. Mcdonald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Mystixins are synthetic peptides that inhibit plasma leakage after tissue injury. We sought to determine the mechanism of the antileakage effect of mystixins, with particular reference to the formation of endothelial gaps in postcapillary venules. Intravenous administration of mystixin-7, a prototype heptapeptide (p-anisoyl-Arg-Lys-Leu-Leu-d-Thi-Ile-d-Leu-NH2), decreased Evans blue leakage induced by substance P (5 μg/kg i.v.) with an ED50 (95% confidence limits) of 130 (76–211) μg/kg in trachea and 52 (27–100) μg/kg in skin of anesthetized F344 rats. Leakage was decreased without a reduction in the number or size of endothelial gaps, visualized by silver deposits after silver nitrate staining. The number of silver deposits per tracheal endothelial cell was 11.4 ± 0.2 (mean ± S.E.) after vehicle pretreatment vs. 13.0 ± 0.8 after mystixin-7 pretreatment (100 μg/kg i.v.). Silver deposit diameter was unchanged at 1.4 ± 0.1 μm. Mean arterial blood pressure dropped by a maximum of 38% from baseline for approximately 10 min after mystixin-7 (100 μg/kg i.v.), then recovered to a plateau at about 13% below baseline. The antileakage effect of mystixin-7 pretreatment in vivo was also demonstrated in aldehyde-fixed vessels perfusedin situ with Evans blue at constant flow (skin, 79% reduction; trachea, 49% reduction), which suggests that mystixin can reduce leakage independent of its hypotensive effect. We conclude that the antileakage effect of mystixin does not depend on reducing the number or size of endothelial gaps, but instead could be caused by residual hypotension, which reduces the negative interstitial fluid pressure toward zero, or clogging of endothelial gaps.

Footnotes

  • Send reprint requests to: Peter Baluk, Ph.D., Cardiovascular Research Institute, University of California, San Francisco, CA 94143-0130.

  • ↵1 This work was supported in part by National Institutes of Health grants HL-24136 and DA-00091.

  • Abbreviations:
    mystixin-7
    p-anisoyl-Arg-Lys-Leu-Leu-d-Thi-Ile-d-Leu-NH2
    CRF
    corticotropin-releasing factor
    bpm
    beats per minute
    mystixin-11
    d-Leu-Ala-Thr-d-Tyr-Arg-Lys-Leu-Leu-d-Thi-d-Ala-Ile-d-Leu-NH2
    • Received July 16, 1997.
    • Accepted October 28, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 284, Issue 2
1 Feb 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anti-inflammatory Mystixin Peptides Inhibit Plasma Leakage Without Blocking Endothelial Gap Formation
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCARDIOVASCULAR PHARMACOLOGY

Anti-inflammatory Mystixin Peptides Inhibit Plasma Leakage Without Blocking Endothelial Gap Formation

Peter Baluk, Natasha W. Fine, Holly A. Thomas, Edward T. Wei and Donald M. Mcdonald
Journal of Pharmacology and Experimental Therapeutics February 1, 1998, 284 (2) 693-699;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherCARDIOVASCULAR PHARMACOLOGY

Anti-inflammatory Mystixin Peptides Inhibit Plasma Leakage Without Blocking Endothelial Gap Formation

Peter Baluk, Natasha W. Fine, Holly A. Thomas, Edward T. Wei and Donald M. Mcdonald
Journal of Pharmacology and Experimental Therapeutics February 1, 1998, 284 (2) 693-699;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preconditioning of Rat Heart with Monophosphoryl Lipid A: A Role for Nitric Oxide
  • TAS-301, an Inhibitor of Smooth Muscle Cell Migration and Proliferation, Inhibits Intimal Thickening after Balloon Injury to Rat Carotid Arteries
  • Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets
Show more CARDIOVASCULAR PHARMACOLOGY

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics